Stifel analyst Adam Walsh suspects GTx shares are down today on balance sheet concerns following the company's earnings report. However, he does not share those worries and remains bullish on the stock ahead of the expected readout of the company's Phase 2 ASTRID trial, which may come as early as October of this year. Additionally, GTx may present further durability data on the trial of enobosarm in postmenopausal women with stress urinary incontinence at the AUA meeting on May 18, which could also move shares higher, said Walsh. He maintains a Buy rating and $45 price target on GTx.